Taken together, our results demonstrate that SUMOylation constitutes a pivotal step of Olig2 PTMs for establishing the TMZ resistance in GBM and disrupting Olig2 SUMOylation may have survival benefit in glioma therapy. The gene discussed is OLIG2; the disease is glioblastoma.